Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Spencer Hammack

Podiatrist, Foot & Ankle Surgery Platteville, WI Doctor of Podiatric Medicine

NPI 1588281448 CMS profile 8170696

1400 Eastside Rd, Platteville, WI 53818

Open in the dashboard

General payments

$20,120

236 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Spencer Hammack of Platteville, WI is reported in the CMS Open Payments database as having received $20,120 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,990 34
2024 General $2,679 41
2023 General $3,187 48
2022 General $5,383 58
2021 General $6,162 50
2020 General $719 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Spencer Hammack
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Spencer Hammack were reported at $1,990. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Spencer Hammack Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $719 $191 $62–$691 $114
2021 $6,162 $329 $104–$1,341 $132
2022 $5,383 $419 $125–$1,611 $149
2023 $3,187 $377 $128–$1,164 $160
2024 $2,679 $394 $134–$1,168 $164
2025 $1,990 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Stryker Corporation $13,031 165 payments
  2. Alpha Orthopedic Systems $4,240 6 payments
  3. Integra LifeSciences Corporation $741 10 payments
  4. Smith+Nephew, Inc. $496 22 payments
  5. Treace Medical Concepts, Inc. $401 5 payments
  6. DePuy Synthes Sales Inc. $192 6 payments
  7. Sanara MedTech Inc. $169 1 payment
  8. Organogenesis Inc. $125 1 payment
  9. Kerecis Limited $121 3 payments
  10. Acera Surgical, Inc. $117 1 payment
  11. Other $486 16 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $10,093 206 payments
  2. Travel and Lodging $5,942 25 payments
  3. Education $4,085 5 payments
Products named General payments · program years 2020–2025
  1. PROSTEP $2,708 22 payments
  2. PROPHECY $1,893 13 payments
  3. INBONE $1,866 12 payments
  4. INFINITY $1,664 15 payments
  5. AUGMENT INJECTABLE $1,575 29 payments
  6. ORTHOLOC 2 LAPIFUSE $1,523 15 payments
  7. VARIAX $1,330 20 payments
  8. INVISION $1,188 7 payments
  9. NA $940 4 payments
  10. 7 X 23MM CITRELOCK IMPLANT $659 10 payments
  11. Other $9,118 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

45

Median for Podiatry: 160

Drug cost

$343

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 11 $229
Meloxicam Generic 34 $114

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$12,929

Medicare's payments for the services billed

Medicare patients

98

Average age 74

Services billed

292

47 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 38%
Chronic kidney disease 31%
Depression 23%
Ischemic heart disease 21%
Osteoporosis 20%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record